Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
A multicentre study with 622 patients has been undertaken to evaluate the efficacy of cyclandelate 1600 mg daily in the treatment of vertigo of circulatory origin in general practice. The characteristics of the patient population were consistent with the diagnosis of vertigo of circulatory origin. Patients with some risk factors, essentially a history of thrombosis and atherosclerotic patients, had more severe symptoms at the onset of the study. During the 3-month period of treatment with cyclandelate, the average global score of vertigo (0-10) decreased from 5.57 to 2.12 and the average scores of frequency, severity and duration of vertigo (0-4) decreased from 2.53, 2.55 and 2.26 to 0.98, 0.89 and 0.84, respectively. Patients previously treated with other anti-ischaemic drugs had similar responses compared to other patients. These results indicate that cyclandelate may be useful in the management of vertigo of circulatory origin in general practice.
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D002561:Cerebrovascular Disorders / Q000150:complications*; D003495:Cyclandelate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D012306:Risk; D012737:Sex Factors; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology
D008333:Mandelic Acids; D003495:Cyclandelate